In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more



 

Global CardioVascular Clinical Trialists Forum 2013

06 - 07 December - Paris, Hotel Pullman Montparnasse France

Why should you attend ?

Practitioners
To gain a better understanding of the results of recent major trials and their impact on clinical practice.

Academics
To engage with practitioners and other stakeholders on the relevance of ongoing research and future trials.

Young Trialist
To learn and network with senior KOLs in order to help shape your future practice and career. Grants are available to young trialists! For more information go to the "Young Investigator Grants" section.

R&D Teams from pharmaceutical and device companies
To present and discuss current research and future trials with scientific and regulatory professionals.

A young clinical trialists Grant

Since 2010,  CVCT Forum offers grant specifically for young clinical trialists interested in learning more about the most up-to-date trials in cardiovascular disease. 

  The Grant: one full scientific registration to attend CVCT 2013 in Paris (including congress materials, lunches and coffee breaks) as well as two nights’ hotel accommodation and a travel grant of up to 200 €.

Apply now for the new CVCT 2013 Young Clinical Trialists Grant

 

Special rates for the Working Group members

Members of the Working Group on Cardiovascular Pharmacology and Drug Therapy can benefit for special registration fees.
Register from here and save up 300€.

Not member yet ? Become a member and save money




Interview of Prof. Luis Ruilope

 

  

"A quite complete picture "

“To me the advantage of CVCT Forum is that it is the only meeting in which you are updated with all the recently finished and ongoing trials,” he said. “Hot topics are debated and this makes quite a complete picture of cardiovascular disease in the sense of how it has to be treated. For people interested in cardiovascular disease CVCT Forum can easily update you on all the things that are relevant in two and a half days.”

Another reason Pr Ruilope keeps coming back to CVCT is for the networking  possibilities. “This meeting has a double advantage,” he explained. “You have the official sessions within the meeting at which senior and junior investigators can sit around one table and discuss. But you also have the opportunity for corridor discussions. These informal conversations improve your knowledge of what others are doing that may not be in the program. 

"A stronger focus on the interaction "

 

 

  “If you attend ESC you have the most complete information, of course, but that is a huge meeting. CVCT is specifically devoted to trials and those experts are more easily accessible than at a big meeting.”

But perhaps the most important benefit of attending CVCT Forum for Pr Ruilope is the way in which content is presented. “The trials that you hear about at CVCT may well be addressed in other meetings,” he remarked. “However, instead of just talking about the content and results of the trial, at CVCT presenters go much deeper into the process and caveats, with critical analysis at the conclusion of a trial on how the data was gathered. Often conferences provide only a few minutes at the end of the presentation for discussion because the speaker has supposedly explained the totality of the topic, leaving nothing open to doubt. At CVCT it is precisely those questions that are at the heart of the conference, with a stronger focus on the interaction than on the lecture.”

The stimulating, interactive session format is what encourages Pr Ruilope to return to CVCT Forum and he is pleased to see the next wave of investigators and other members of the medical trial community so engaged with the meeting. “Young investigators today require imagination,” he said. “The pharmaceutical industry requires imagination, too, not only for new drugs but also for new trials that profile those drugs. If we sit down for an hour I can give you countless new ideas for trials but perhaps not one of them will become a reality. CVCT brings the funding institutions – both government and industry – to the place where they can meet the trialists and prepare together for work ahead.”

 

Past meeting reports & recordings